Loading patent…
AssigneesNational University Corporation Kumamoto University, University of Occupational and Enviromental Health, Japan, SBI Pharmaceuticals Co., Ltd.
InventorsTetsuya Yoneda, Shigeru Nishizawa, Junkoh Yamamoto, Tohru Tanaka, Hidenori Itoh
Estimating the term…
[Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.
A method for diagnosing glioblastoma in a subject, comprising:
Dependencies are inferred from the claim text.